Herausforderung gastrointestinale Stromatumoren

Zusammenfassung

Gastrointestinale Stromatumoren sind die häufigsten mesenchymalen Neoplasien des Verdauungstraktes. In lokalisierten Stadien erfolgt eine chirurgische Resektion, je nach Größe und Risikokonstellation begleitet durch eine adjuvante oder neoadjuvante Therapie. Für das metastasierte Stadium stehen heute mehrere Therapielinien zur Verfügung. Die Mutationsanalyse aus dem Tumormaterial ist für die Therapieplanung von zentraler Bedeutung.

Publication History

Article published online:
28 October 2021

• Literatur

• 1 Dietrich C. Hrsg. Endosonographie. Stuttgart: Thieme; 2008.
• 2 Chandrasekhara V, Ginsberg GG. Endoscopic management of gastrointestinal stromal tumors. Curr Gastroenterol Rep 2011; 13: 532-539
• 3 Chen TH, Hsu CM, Chu YY. et al. Association of endoscopic ultrasonographic parameters and gastrointestinal stromal tumors (GISTs): can endoscopic ultrasonography be used to screen gastric GISTs for potential malignancy?. Scand J Gastroenterol 2016; 51: 374-377
• 4 Casali PG. Gastrointestinal stromal tumors: ESMO-EUROCAN clinical practice guideline. Ann Oncol 2018; 29 (Suppl. 04) iv68-iv78
• 5 Hohenberger P, Langer C, Wendtner CM. et al. Neoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label Phase II study in KIT- or PDGFRA-positive tumors. J Clin Oncol 2012; 30 (Suppl. 15) 10031
• 6 Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83
• 7 Joensuu H, Vehtari A, Riihimäki J. et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012; 13: 265-274
• 8 Joensuu H, Eriksson M, Sundby-Hall K. et al. Survival Outcomes Associated With 3 Years vs. 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Followup. JAMA Oncol 2020; 6: 1241-1246
• 9 ClinicalTrials.gov Identifier: NCT02413736. Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients with Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study. Im Internet (Stand 10.04.2021): https://clinicaltrials.gov/ct2/show/NCT02413736
• 10 Demetri GD, von Mehren M, Blanke CD. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
• 11 Blanke CD, Demetri GD, von Mehren M. et al. Long-termresults from a randomized phase II trial of standard-versus higherdose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625
• 12 Heinrich MC, Rankin C, Blanke CD. et al. Correlation of Longterm Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 2017; 3: 944-952
• 13 Casali PG, Zalcberg J, Le Cesne A. et al. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. J Clin Oncol 2017; 35: 1713-1720
• 14 Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1640 Patients. J Clin Oncol 2010; 28: 1247-1253
• 15 Blay JY, Le Cesne A, Ray-Coquard I. et al. Prospective Multicentric Randomized Phase III Study of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113
• 16 Demetri GD, van Oosterom AT, Garrett CR. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338
• 17 Reichardt P, Kang YK, Rutkowski P. et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 2015; 121: 1405-1413
• 18 Heinrich MC, Maki RG, Corless CL. et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359
• 19 Demetri GD, Reichardt P, Kang YK. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295-302
• 20 Janku F, Razak ARA, Gordon MS. et al. Encouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST). Ann Oncol 2017; 28 (Suppl. 05) v521-v538
• 21 Blay JY, Serrano C, Heinrich MC. et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 923-934
• 22 ClinicalTrials.gov Identifier: NCT03673501. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue). First posted: 2018. Im Internet (Stand 10.04.2021): https://clinicaltrials.gov/ct2/show/NCT03673501
• 23 ClinicalTrials.gov Identifier: NCT04148092. Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST. First posted: 2019. Im Internet (Stand 10.04.2021): https://clinicaltrials.gov/ct2/show/NCT04148092
• 24 Heinrich MC, Jones RL, von Mehren M. et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21: 935-946